Corcept Therapeutics (CORT) Rockets On FDA Approval; Analyst Sees Peak U.S. Sales of $300M

Go back to Corcept Therapeutics (CORT) Rockets On FDA Approval; Analyst Sees Peak U.S. Sales of $300M